Evidence map›Paper›PMID 38434002›Full record

ArticleF1000Research2022

Lessons from COVID-19 for GCR governance: a research agenda.

Jochem Rietveld, Tom Hobson, Shahar Avin, Lalitha Sundaram, Lara Mani

Abstract read
In one paragraph

Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jochem RietveldCentre for the Study of Existential Risk, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6743-424X
Tom HobsonCentre for the Study of Existential Risk, University of Cambridge, Cambridge, UK.
Shahar AvinCentre for the Study of Existential Risk, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7859-1507
Lalitha SundaramCentre for the Study of Existential Risk, University of Cambridge, Cambridge, UK.
Lara ManiCentre for the Study of Existential Risk, University of Cambridge, Cambridge, UK.ORCID 0000-0003-2967-7499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Lessons from Covid-19 Research Agenda offers a structure to study the COVID-19 pandemic and the pandemic response from a Global Catastrophic Risk (GCR) perspective. The agenda sets out the aims of our study, which is to investigate the key decisions and actions (or failures to decide or to act) that significantly altered the course of the pandemic, with the aim of improving disaster preparedness and response in the future. It also asks how we can transfer these lessons to other areas of (potential) global catastrophic risk management such as extreme climate change, radical loss of biodiversity and the governance of extreme risks posed by new technologies. Our study aims to identify key moments- 'inflection points'- that significantly shaped the catastrophic trajectory of COVID-19. To that end this Research Agenda has identified four broad clusters where such inflection points are likely to exist: pandemic preparedness, early action, vaccines and non-pharmaceutical interventions. The aim is to drill down into each of these clusters to ascertain whether and how the course of the pandemic might have gone differently, both at the national and the global level, using counterfactual analysis. Four aspects are used to assess candidate inflection points within each cluster: 1. the information available at the time; 2. the decision-making processes used; 3. the capacity and ability to implement different courses of action, and 4. the communication of information and decisions to different publics. The Research Agenda identifies crucial questions in each cluster for all four aspects that should enable the identification of the key lessons from COVID-19 and the pandemic response.

Indexed as

COVID-19BiodiversityClimate ChangeCommunicationHumansPandemicsCoronacounterfactual analysisCOVID-19GCRglobal catastrophic riskspandemicpandemic response

Identifiers

PMID38434002
PMCPMC10904943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.